Merlin L. Robb

Merlin L. Robb

Auto-generated profile, based on publicly available information

Merlin L. Robb

US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2016 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MRMerlin L. Robb
Merlin L. Robb
LELeigh A. Eller
Leigh A. Eller
HKHannah Kibuuka
Hannah Kibuuka
KRKathleen Rono
Kathleen Rono
LMLucas Maganga
Lucas Maganga
NMNelson L. Michael
Nelson L. Michael
Acute human immunodeficiency virus type 1 (HIV-1) infection is a major contributor to transmission of HIV-1. An understanding of acute HIV-1 infection may be important in the development of treatment strategies to eradicate HIV-1 or achieve a functional cure. We performed twice-weekly qualitative plasma HIV-1 RNA nucleic acid testing in 2276 volunteers who were at high risk for HIV-1 infection. For participants in whom acute HIV-1 infection was detected, clinical observations, quantitative measurements of plasma HIV-1 RNA levels (to assess viremia) and HIV antibodies, and results of immunophenotyping of lymphocytes were obtained twice weekly. Fifty of 112 volunteers with acute HIV-1 infection had two or more blood samples collected before HIV-1 antibodies were detected. The median peak viremia (6.7 log10 copies per milliliter) occurred 13 days after the first sample showed reactivity on nucleic acid testing. Reactivity on an enzyme immunoassay occurred at a median of 14 days. The nadir of viremia (4.3 log10 copies per milliliter) occurred at a median of 31 days and was nearly equivalent to the viral-load set point, the steady-state viremia that persists durably after resolution of acute viremia (median plasma HIV-1 RNA level, 4.4 log10 copies per milliliter). The peak viremia and downslope were correlated with the viral-load set point. Clinical manifestations of acute HIV-1 infection were most common just before and at the time of peak viremia. A median of one symptom of acute HIV-1 infection was recorded at a median of two study visits, and a median of one sign of acute HIV-1 infection was recorded at a median of three visits. The viral-load set point occurred at a median of 31 days after the first detection of plasma viremia and correlated with peak viremia. Few symptoms and signs were observed during acute HIV-1 infection, and they were most common before peak viremia. (Funded by the Department of Defense and the National Institute of Allergy and Infectious Diseases.)

6 October 2014 in BMC Genomics
Verified
Journal Article
Open access
PDF file
PEPhilip K Ehrenberg
Philip K Ehrenberg
AGAviva Geretz
Aviva Geretz
KBKaren M Baldwin
Karen M Baldwin
RARichard Apps
Richard Apps
VPVictoria Polonis
Victoria Polonis
RTRasmi Thomas
Rasmi Thomas
Unambiguous human leukocyte antigen (HLA) typing is important in transplant matching and disease association studies. High-resolution HLA typing that is not restricted to the peptide-binding region can decrease HLA allele ambiguities. Cost and technology constraints have hampered high-throughput and efficient high resolution unambiguous HLA typing. We have developed a method for HLA genotyping that preserves the very high-resolution that can be obtained by next-generation sequencing (NGS) but also achieves substantially increased efficiency. Unambiguous HLA-A, B, C and DRB1 genotypes can be determined for 96 individuals in a single run of the Illumina MiSeq. Long-range amplification of full-length HLA genes from four loci was performed in separate polymerase chain reactions (PCR) using primers and PCR conditions that were optimized to reduce co-amplification of other HLA loci. Amplicons from the four HLA loci of each individual were then pooled and subjected to enzymatic library generation. All four loci of an individual were then tagged with one unique index combination. This multi-locus individual tagging (MIT) method combined with NGS enabled the four loci of 96 individuals to be analyzed in a single 500 cycle sequencing paired-end run of the Illumina-MiSeq. The MIT-NGS method generated sequence reads from the four loci were then discriminated using commercially available NGS HLA typing software. Comparison of the MIT-NGS with Sanger sequence-based HLA typing methods showed that all the ambiguities and discordances between the two methods were due to the accuracy of the MIT-NGS method. The MIT-NGS method enabled accurate, robust and cost effective simultaneous analyses of four HLA loci per sample and produced 6 or 8-digit high-resolution unambiguous phased HLA typing data from 96 individuals in a single NGS run.

15 February 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
HTHiroshi Takata
Hiroshi Takata
SBSupranee Buranapraditkun
Supranee Buranapraditkun
CKCari Kessing
Cari Kessing
JFJames L. K. Fletcher
James L. K. Fletcher
RMRoshell Muir
Roshell Muir
LTLydie Trautmann
Lydie Trautmann
Potent CD8 + T cells endowed with effector functions able to kill HIV-producing cells and reduce the seeding of the HIV reservoir are only detected at peak viremia in acute HIV infection.

4 March 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
LLLouise Leyre
Louise Leyre
EKEugène Kroon
Eugène Kroon
CVClaire Vandergeeten
Claire Vandergeeten
CSCarlo Sacdalan
Carlo Sacdalan
DCDonn J. Colby
Donn J. Colby
NCNicolas Chomont
Nicolas Chomont
The timing and location of the establishment of the viral reservoir during acute HIV infection remain unclear. Using longitudinal blood and tissue samples obtained from HIV-infected individuals at the earliest stage of infection, we demonstrate that frequencies of infected cells reach maximal values in gut-associated lymphoid tissue and lymph nodes as early as Fiebig stage II, before seroconversion. Both tissues displayed higher frequencies of infected cells than blood until Fiebig stage III, after which infected cells were equally distributed in all compartments examined. Initiation of antiretroviral therapy (ART) at Fiebig stages I to III led to a profound decrease in the frequency of infected cells to nearly undetectable level in all compartments. The rare infected cells that persisted were preferentially found in the lymphoid tissues. Initiation of ART at later stages (Fiebig stages IV/V and chronic infection) induced only a modest reduction in the frequency of infected cells. Quantification of HIV DNA in memory CD4+ T cell subsets confirmed the unstable nature of most of the infected cells at Fiebig stages I to III and the emergence of persistently infected cells during the transition to Fiebig stage IV. Our results indicate that although a large pool of cells is infected during acute HIV infection, most of these early targets are rapidly cleared upon ART initiation. Therefore, infected cells present after peak viremia have a greater ability to persist.

15 February 2010 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
HKHannah Kibuuka
Hannah Kibuuka
RKRobert Kimutai
Robert Kimutai
LMLeonard Maboko
Leonard Maboko
FSFred Sawe
Fred Sawe
MSMirjam S. Schunk
Mirjam S. Schunk
MRMerlin L. Robb
Merlin L. Robb
Background. Human immunodeficiency virus (HIV) vaccine development remains a global priority. We describe the safety and immunogenicity of a multicla

1 November 2014 in EBioMedicine
Verified
Journal Article
Open access
SZSusan Zolla-Pazner
Susan Zolla-Pazner
PEPaul T. Edlefsen
Paul T. Edlefsen
MRMorgane Rolland
Morgane Rolland
XKXiang-Peng Kong
Xiang-Peng Kong
ADAllan DeCamp
Allan DeCamp
PGPeter B. Gilbert
Peter B. Gilbert
To evaluate the role of V3-specific IgG antibodies (Abs) in the RV144 clinical HIV vaccine trial, which reduced HIV-1 infection by 31.2%, the anti-V3 Ab response was assessed. Vaccinees' V3 Abs were highly cross-reactive with cyclic V3 peptides (cV3s) from diverse virus subtypes. Sieve analysis of CRF01_AE breakthrough viruses from 43 vaccine- and 66 placebo-recipients demonstrated an estimated vaccine efficacy of 85% against viruses with amino acids mismatching the vaccine at V3 site 317 (p = 0.004) and 52% against viruses matching the vaccine at V3 site 307 (p = 0.004). This analysis was supported by data showing that vaccinees' plasma Abs were less reactive with I307 when replaced with residues found more often in vaccinees' breakthrough viruses. Simultaneously, viruses with mutations at F317 were less infectious, possibly due to the contribution of F317 to optimal formation of the V3 hydrophobic core. These data suggest that RV144-induced V3-specific Abs imposed immune pressure on infecting viruses and inform efforts to design an HIV vaccine.